Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
SAMFORD UNIVERSITY GLOBAL DRUG INFORMATION SERVICE’S C L I PS CURRENT LITERATURE AND INFORMATION FOR PHARMACISTS® http://pharmacy.samford.edu/msop_dic.aspx Volume 15 (Issue 25) July 11, 2011 EFFECT OF ADDING A THIRD AGENT IN UNCONTROLLED TYPE 2 DIABETES In many patients with Type 2 diabetes mellitus (T2DM), long-term glucose control is not achieved or maintained through lifestyle modifications or combination therapy with metformin and sulfonylurea. A third agent, such as insulin, αglucosidase inhibitors (acarbose, miglitol), thiazolidinediones (pioglitazone, rosiglitazone), glucagon-like peptide-1 agonists (exenatide, liraglutide),or dipeptidyl peptidase-4 inhibitors (sitagliptin, saxagliptin, linagliptin) are often added in an effort to achieve long-term glucose control. This issue of CLIPs briefly summarizes a meta-analysis that sought to determine if any of these drug classes offer greater benefit as a third agent with regard to changes in hemoglobin A1c (HgA1c) levels, weight or frequency of severe hypoglycemic episodes in patients with uncontrolled T2DM. If you need further information, please contact the Samford University Drug Information Service at (205) 726-2659. Gross JL, Kramer CK, Leitão CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011 May 17;154:672-679. Methods Analysis included 18 randomized, controlled trials (n=4535) that evaluated the effect on glucose control with addition of a third antihyperglycemic agent to metformin and sulfonylurea in patients with uncontrolled T2DM. Patients ≥18 year or older with HbA1c level greater than 7.0% on stable therapy with metformin (≥1000 mg/day) and a sulfonylurea (≥50% of max dose) for at least 3 months. Endpoints evaluated included mean change in HbA1c level, weight, and frequency of severe hypoglycemic episodes (blood glucose ≤35 mg/dL). Results A decrease in HbA1c was seen with each class of antihyperglycemics (see Table) Compared to placebo, noninsulin agents reduced HbA1c a mean of 0.96% (95% CI, -1.11 to -0.81). Compared to insulin, noninsulin antihyperglycemic agents, as a whole, led to a mean increase of 0.29% (95% CI, 0.06 to 0.51) in HbA1c level in comparison to insulin. Noninsulin Antihyperglycemic Agents or Insulins vs. Placebo Difference in HbA1c level, % Intervention (# studies) Weighted Mean (95% CI) All agents (9) -0.96 (-1.11 to -0.81) Insulin (2) -0.71 (-0.95 to -0.47) Thiazolidinediones (3) -1.15 (-1.35 to -0.95) Acarbose (1) -0.60 (-1.16 to -0.04) Glucagon-like peptide-1 [GLP-1] agonists (2) -1.04 (-1.24 to -0.85) Dipeptidyl peptidase-4 [DPP-4] inhibitors (1) -0.89 (-1.11 to -0.67) Noninsulin Antihyperglycemic Agents vs. Insulins All agents (10) 0.29 (0.06 to 0.51) Thiazolidinediones (6) 0.22 (0.07 to 0.37) Acarbose (1) 0.20 (-0.60 to 1.00) GLP-1 agonists (3) 0.10 (-0.28 to 0.42) CI=confidence interval CONTINUED NEXT PAGE Results (continued) Changes in HgA1c levels were not associated with baseline HgA1c levels, duration of diabetes or baseline body mass index (BMI). Changes in weight varied among drug classes. o Compared to placebo, insulin caused a significant increase in weight (2.31 kg [95% CI, 0.13 to 4.48 kg]) and acarbose caused a significant decrease in weight (-0.96 kg [95% CI -1.80 to -0.12]). o Compared to insulin, thiazolidinediones were associated with a weight increase (1.67 kg [95% CI, 0.98 to 2.36 kg]) and GLP-1 agonists with a weight decrease (-4.99 kg [95% CI, -5.80 to-4.18 kg]). Data on changes in weight were not available for the DPP-4 inhibitors. The frequency of hypoglycemic episodes could not be analyzed because many studies did not report this information. o Compared to placebo, severe hypoglycemic episodes were reported in two patients taking insulin (2/335), in one taking acarbose (1/41) and five patients taking GLP-1 agonists (5/466). o Overall, severe hypoglycemic episodes occurred at twice the frequency in patients taking insulin compared to patients taking noninsulin antihyperglycemics (2.7% [15/566] vs. 1.1% [6/553], respectively). Increased frequency was also noted with the GLP-1 agonists (4.1% [6/145] vs. 2.2% [3/138], respectively) and the thiazolidinediones (2.1% [9/421] vs. 0.07% [3/415], respectively). No data was available for acarbose or the DPP-4 inhibitors compared with insulin. Discussion Direct meta-analysis compared all agents against placebo and noninsulin agents against insulin. Network meta-analysis compared all agents against each other. Only results of the direct meta-analysis are presented. Results suggest that adding a third agent is beneficial, but does not distinguish which drug class is superior for reducing HbA1c. Studies suggest that patients taking insulin are at greater risk of weight gain than patients taking any of the other noninsulin antihyperglycemics. Among the noninsulin agents, weight gain was noted with the thiazolidinediones and weight loss was noted with acarbose and the GLP-1 agonists. The other noninsulin antihyperglycemic agents did not have a significant effect on weight gain or loss. Differences in the occurrence of severe hypoglycemia were found between the drug classes. Insulin caused the most risk of severe hypoglycemia followed by the GLP-1 agonists and the thiazolidinediones. This analysis is limited by short-term trials (<1 year) with varied quality and indirect comparisons which increased the uncertainty of the results and conclusions. Summary No apparent difference in benefit between drug classes (insulin, α-glucosidase inhibitors, thiazolidinediones, GLP-1 agonists or DPP-4 inhibitors) exist when choosing a third agent for the treatment of patients with uncontrolled T2DM who are already taking metformin and a sulfonylurea. Selection of a third drug should include consideration of the patient’s clinical needs, such as importance of weight changes and potential risk of hypoglycemia. 2 Prepared by: Rhonda Hamilton, Pharm.D. Candidate Reviewed by: Rachel Slaton, Pharm.D., BCPS Effect of adding a third agent in uncontrolled type 2 diabetes. CLIPs- Current Literature and Information for Pharmacists. 2011 July 11;15(25):1-2.